Physicians' Academy for Cardiovascular Education

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner, MD - University of Würzburg, Germany - Online CME

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Video navigation menu

  • EMPA-REG OUTCOME: eGFR over 3 years 02:32
  • New onset or worsening of nephropathy 04:20
  • Outcome in patients with pre-existing CKD (renal population)  08:28
  • New onset or worsening of nephropathy: subgroup analysis  10:06
  • Safety 12:30

Educational information

This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.


Professor Christoph Wanner, MD - University of Würzburg, Germany


This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.


Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View slides of prof. Wanner


This is available as accredited online CME for members. Click the button below to enroll:


Share this page with your colleagues and friends: